Brain cancer's most devastating trait may become its downfall. Glioblastoma's tendency to infiltrate healthy tissue through chemical signals could be redirected to trap tumor cells in treatment zones, fundamentally changing how medicine approaches the most lethal brain cancer. The CXCL12/CXCR4 chemokine pathway normally guides glioblastoma cells deeper into brain tissue by creating molecular breadcrumb trails. This mechanism drives the cancer's notorious ability to evade surgical removal and resist treatments. Scientists have engineered hydrogel platforms that exploit this natural homing behavior by presenting concentrated CXCL12 signals that essentially hijack tumor cell navigation systems. The modified hydrogels act as decoy destinations, drawing invasive cells away from healthy brain regions while simultaneously delivering sustained therapeutic payloads directly at the capture site. This biomimetic approach circumvents the blood-brain barrier challenge that has long frustrated systemic drug delivery attempts. The strategy represents a paradigm shift from trying to kill scattered tumor cells throughout the brain toward consolidating them in controllable treatment zones. Current glioblastoma therapies achieve median survivals of just 15 months despite maximum surgical resection and aggressive chemoradiation protocols. While promising in principle, this chemokine-guided trapping concept remains largely theoretical pending comprehensive preclinical validation. The approach's success will depend on whether engineered CXCL12 gradients can consistently outcompete the brain's natural signaling environment and whether captured cells retain sensitivity to co-delivered therapeutics. If validated, this could establish localized cell capture as a new treatment pillar alongside surgery and radiation.